Methylcobalamin deficiency type cblG

Cognitive impairment in methylcobalamin deficiency type cblG often manifests as difficulties with memory, attention, and problem-solving skills. This symptom is caused by disruptions in methionine synthase activity, leading to impaired methylation processes critical for brain function. Over time, cognitive impairment can progress to more severe neurological deficits if left untreated. It affects daily life by hindering academic and occupational performance, but early intervention with vitamin B12 supplementation can help mitigate these effects.

Developmental delay is characterized by slower achievement of developmental milestones such as walking, talking, and social interaction. The biological mechanism involves reduced synthesis of methionine and S-adenosylmethionine, essential for myelin formation and neurotransmitter synthesis. Without treatment, developmental delays can become more pronounced, potentially leading to long-term disabilities. Early diagnosis and treatment with cobalamin can improve developmental outcomes and enhance quality of life.

Megaloblastic anemia presents with fatigue, pallor, and shortness of breath due to ineffective erythropoiesis. This condition arises from impaired DNA synthesis in red blood cell precursors, a direct consequence of cobalamin deficiency. If untreated, anemia can worsen, leading to severe fatigue and reduced exercise tolerance. Treatment with vitamin B12 can correct the anemia and alleviate symptoms, improving energy levels and daily functioning.

Thrombotic microangiopathy is marked by the formation of small blood clots in the microvasculature, causing organ damage. It is caused by endothelial injury due to elevated homocysteine levels, a result of impaired methionine synthase activity. This condition can progress to kidney damage and neurological complications if not addressed. Management includes vitamin B12 supplementation and supportive care to prevent further thrombotic events.

Neurological abnormalities can include seizures, ataxia, and peripheral neuropathy, reflecting widespread nervous system involvement. These symptoms result from disrupted methylation and myelin synthesis due to cobalamin deficiency. Over time, neurological symptoms can become debilitating, affecting mobility and coordination. Early treatment with cobalamin can stabilize or improve neurological function, enhancing patient autonomy and quality of life.

Hypertension in this context may present with headaches, dizziness, and visual disturbances. It is thought to be linked to vascular changes associated with elevated homocysteine levels. If untreated, hypertension can lead to cardiovascular complications such as stroke or heart attack. Management involves controlling blood pressure with medication and addressing the underlying cobalamin deficiency to reduce homocysteine levels.

Proteinuria is characterized by the presence of excess protein in the urine, often detected during routine screening. It may be associated with kidney damage due to thrombotic microangiopathy. Over time, persistent proteinuria can indicate progressive renal impairment, necessitating further evaluation and intervention. Treatment focuses on managing the underlying cause and monitoring kidney function to prevent long-term damage.

Hematuria presents as blood in the urine, which can be visible or detected microscopically. It may result from renal involvement in thrombotic microangiopathy or other vascular changes. If persistent, hematuria can signal ongoing kidney damage and requires further investigation. Addressing the underlying methylcobalamin deficiency and managing thrombotic risks are crucial to resolving this symptom.

Clinicians look for signs of developmental delay, neurological symptoms, and failure to thrive. A detailed family history of metabolic disorders or consanguinity is important. Physical examination may reveal hypotonia, lethargy, or seizures. This step helps prioritize further diagnostic testing and rule out other common metabolic disorders.

MRI of the brain is commonly used to assess structural abnormalities. Abnormalities such as white matter changes or cerebral atrophy may be visible. These findings support the diagnosis of a metabolic disorder and help exclude other neurological conditions. Imaging is not definitive but guides further laboratory and genetic testing.

Blood tests are ordered to measure homocysteine and methylmalonic acid levels. Elevated homocysteine and normal methylmalonic acid levels suggest methionine synthase deficiency. Abnormal results prompt further investigation into cobalamin metabolism. These results guide the decision to proceed with genetic testing.

The MTR gene is sequenced to identify mutations associated with cblG deficiency. Mutations such as missense or nonsense changes confirm the diagnosis. Genetic results provide a definitive diagnosis and inform family counseling regarding recurrence risks. They also guide management and potential prenatal testing in future pregnancies.